Indegene Limited has appointed Jill Mary De Simone as an Independent Director to its board, with shareholders approving the move at the company’s 28th Annual General Meeting held on August 13, 2026 via video conference. The decision underscores Indegene’s continuing focus on strengthening governance and strategic oversight as it navigates growth across its global life sciences services footprint.
De Simone is a seasoned biopharmaceutical executive with broad international experience in leadership and governance. Her career includes serving as President of U.S. Oncology at Merck, and senior roles across Merck, Teva and Bristol Myers Squibb, where she handled full P&L responsibilities and led launches of transformative therapies in oncology, HIV, women’s health and general medicine. Today, she advises preclinical and early-stage companies on commercialization and leadership transitions, sits on boards of public and private life sciences entities, and chairs advisory boards focused on AI in healthcare. Her background is built on strategic acumen, authentic leadership, and a commitment to purpose-driven cultures.
The appointment, for a three-year term from January 22, 2026 to January 21, 2029, positions Indegene to benefit from De Simone’s governance experience and broad industry perspective as the company expands its strategic initiatives and collaborates with partners across the healthcare ecosystem. Notably, her continuous involvement with boards and advisory groups centered on technology-enabled healthcare signals an alignment with Indegene’s emphasis oninnovation and robust governance to sustain growth in a rapidly evolving market.
This move adds a seasoned independent voice to the board, reinforcing Indegene’s emphasis on governance and strategic guidance at a time when the company is scaling its healthcare capabilities and services globally.